文献速递妇科生殖医学

利拉鲁肽对多囊卵巢综合征卵巢功能障碍的影响:一项随机临床试验

Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.
PubMed 文献 · Reprod Biomed Online · 2017-04-24

这项双盲随机试验将72名多囊卵巢综合征女性按2:1分配至利拉鲁肽1.8 mg/日组或安慰剂组,随访26周。利拉鲁肽组体重下降5.2 kg(95% CI 3.0至7.5,P<0.0001),出血比率改善0.28(95% CI 0.20至0.36,P<0.001),组间差异0.14(95% CI 0.03至0.24,P<0.05),性激素结合球蛋白升高、游离睾酮下降,卵巢体积减小。利拉鲁肽改善了超重多囊卵巢综合征女性的卵巢功能标志物,可能是一种可行的干预措施。

要点

  • 利拉鲁肽组体重下降5.2 kg(95% CI 3.0至7.5,P<0.0001)。
  • 利拉鲁肽组出血比率0.28(95% CI 0.20至0.36,P<0.001),安慰剂组0.14(95% CI 0.02至0.26,P<0.05),组间差异0.14(95% CI 0.03至0.24,P<0.05)。
  • 利拉鲁肽组恶心和便秘更常见。

核心结论

  • 利拉鲁肽改善了超重多囊卵巢综合征女性的卵巢功能标志物,可能是一种可行的干预措施。

研究设计与样本

  • 双盲随机试验,72名多囊卵巢综合征女性按2:1比例分配至利拉鲁肽1.8 mg/日组或安慰剂组,随访26周。

主要发现

  • 利拉鲁肽组体重下降5.2 kg(95% CI 3.0至7.5,P<0.0001),优于安慰剂。
  • 利拉鲁肽组出血比率0.28(95% CI 0.20至0.36,P<0.001),安慰剂组0.14(95% CI 0.02至0.26,P<0.05),组间差异0.14(95% CI 0.03至0.24,P<0.05)。
  • 利拉鲁肽组性激素结合球蛋白升高7.4 nmol/L(95% CI 4.1至10.7),游离睾酮下降0.005 nmol/L(95% CI -0.009至-0.001)。
  • 利拉鲁肽组较安慰剂组卵巢体积减小1.6 ml(95% CI -3.3至0.1)。
  • 利拉鲁肽组恶心和便秘更常见。

临床怎么用

  • 作者认为利拉鲁肽改善了超重多囊卵巢综合征女性的卵巢功能标志物,可能是一种可行的干预措施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polycystic ovary syndrome (PCOS) encompasses an ovarian and a metabolic dysfunction. Glucagon-like peptide-1 (GLP-1) analogues facilitate weight loss and ameliorate metabolic dysfunction in overweight women with PCOS, but their effect on ovarian dysfunction is scarcely reported. In a double-blind, randomized trial, 72 women with PCOS were allocated to intervention with the GLP-1 analogue liraglutide or placebo (1.8 mg/day), in a 2:1 ratio. At baseline and 26-week follow-up, bleeding pattern, levels of AMH, sex hormones and gonadotrophins were assessed and ovarian morphology evaluated. Liraglutide caused 5.2 kg (95% CI 3.0 to 7.5, P < 0.0001) weight loss compared with placebo. Bleeding ratio improved with liraglutide: 0.28 (95% CI 0.20 to 0.36, P < 0.001); placebo: 0.14 (95% CI 0.02 to 0.26, P < 0.05); between-group difference: 0.14 (95% CI 0.03 to 0.24, P < 0.05). In the liraglutide group, SHBG increased by 7.4 nmol/L (95% CI 4.1 to 10.7) and free testosterone decreased by 0.005 nmol/L (95% CI -0.009 to -0.001). Ovarian volume decreased by -1.6 ml (95% CI -3.3 to 0.1) with liraglutide versus placebo. Nausea and constipation were more prevalent in the liraglutide group. Liraglutide improved markers of ovarian function in overweight women with PCOS, and might be a possible intervention.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Nylander M, Frøssing S, Clausen HV, et al. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017. PMID: 28479118. doi:10.1016/j.rbmo.2017.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。